Phosducin-like 3 (PDCL3) is a member of the phosducin-like protein family, which is known for its role in binding to the beta-gamma subunits of G proteins. PDCL3 shares a significant amino acid sequence homology with phosducin and is considered a potential regulator of heterotrimeric G proteins . This protein is characterized by a thioredoxin-like structural domain and evolutionary conservation .
The mouse anti-human PDCL3 monoclonal antibody is derived from the hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with a recombinant human PDCL3 protein. The protein used for immunization is typically purified from E. coli and spans 1-239 amino acids . The antibody is purified from mouse ascitic fluids using protein-A affinity chromatography .
PDCL3 plays a crucial role in various biological processes, including angiogenesis and apoptosis . It has been identified as a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma (LIHC). High PDCL3 expression is linked to poorer clinical staging and prognosis in LIHC . Additionally, PDCL3 is involved in modulating immune responses and has positive correlations with multiple immune checkpoint genes .
The precise regulatory mechanisms of PDCL3 in cancer are still under investigation. However, enrichment analysis of PDCL3-associated genes has revealed its involvement in various immune responses . Further research is needed to fully understand the regulatory pathways and mechanisms through which PDCL3 exerts its effects in different cancer types.